PERTH, Australia, Nov. 10, 2014 /PRNewswire/ -- ASX listed
Resonance Health (ASX:RHT) officially launched an innovative new
diagnostic imaging solution for liver patients worldwide at the
American Association for the Study of Liver Diseases annual
conference in Boston this
week.
HepaFat-Scan technology was developed in collaboration with the
University of Western Australia,
and uses magnetic resonance imaging (MRI) scanners in a
non-invasive manner, to measure the concentration of fat in the
human liver.
This is the first and only technology of its kind to obtain
regulatory clearances in the USA -
FDA, Europe - CE Mark, and
Australia - TGA and has also just won the coveted Western
Australian Innovation of the Year award at the 2014 WA Innovator of
the Year Awards.
Chief Scientist Professor Tim St
Pierre said HepaFat-Scan addresses the growing prevalence of
fatty liver disease in Australia
and many other countries, as well as an unmet need for non-invasive
diagnostic tools to diagnose and monitor liver disease.
"It reports volumetric fraction of fat in the liver, a measure
that can be directly compared to a volumetric biopsy fat fraction
measurement, providing patients and doctors with a more accurate
diagnostic tool as part of a structured intervention protocol or
clinical research trial."
Compared with the traditional gold standard for clinical
assessment of liver fat - histopathological assessment,
HepaFat-Scan is a much more objective and non-invasive MRI based
method with greater reproducibility and significantly reduced
sampling error.
Hence, clinicians and patients can greatly benefit from an
accurate HepaFat-Scan measurement of liver fat to monitor and
manage efficacy of treatment, and to provide prognoses for fatty
liver disease and associated multiple hepatic and systemic
disorders and many other related diseases.
All image analysis and reporting services are provided from
Resonance Health's ISO 13485 certified Perth based facility and are utilised by
hospitals in over 20 countries, and in international clinical
trials.
The Innovator of the Year Program is an annual event run by the
Western Australian Department of Commerce that fosters a culture of
innovation in Western Australia
and acknowledges the achievements of WA's leading innovation
enterprises.
For further information please contact:
Resonance Health
Liza Dunne
Managing Director
T: +61 8 9286 5300
E: lizad@resonancehealth.com
Adrian Bowers
Company Secretary
T: +61 8 9286 5300
E: adrianb@resonancehealth.com
SOURCE Resonance Health
